Jerome Lemoine is a French transfection specialist who has completed his PhD thesis in the Center for Pharmacogenetics of the School of Pharmacy at the University of Pittsburgh in Leaf Huang’s lab from 2001 to 2005. He has pursued his scientific career in the field of transfection in Robert Debs’ lab in San Francisco, as a postdoctoral fellow.
Then, he has returned back to France, in order to perfect an in vivo messenger RNA delivery biotechnology and found a startup company.
After over three years of research, he has founded Messenger Biopharma in September 2015 whose President he is.
From April 2016 on, Messenger Biopharma’s R&D team has first invented a second-generation messenger RNA that is much cheaper than a traditional mRNA (Cf. Aegis™ biotechnology). Then, it has discovered a cheap and potent striated muscle mRNA delivery system (Cf. Pheidippides™ biotechnology). Finally, the R&D team has perfected the Asclepios biotechnology, which is a very potent ex vivo mRNA transfection technology for human cells, such as stem cells.
Messenger Biopharma is housed by Biopôle Clermont Limagne in Riom, France. The company rents 60 square meters of molecular biology and cell culture laboratories, as well as 90 square meters of rodent housing facility and a 10 square meter-office.
OST Group, a company located in Clermont-Ferrand, became a shareholder in July 2019.